Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Puromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPEPPS | P55786 | 12/20 | 0.94 |
| ▸ | ANPEP | P15144 | 10/20 | 0.94 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.94 |
| ▸ | TP53 | P04637 | 2/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.94 |
| ▸ | LMNA | P02545 | 1/20 | 0.94 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.94 |
| ▸ | HTT | P42858 | 1/20 | 0.93 |
| ▸ | NPC1 | O15118 | 1/20 | 0.93 |
| ▸ | RAB9A | P51151 | 1/20 | 0.93 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Puromycin SCHEMBL14583797 | 0.97 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL12799451 | 0.97 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22409382 | 0.97 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL18190282 | 0.97 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21306559 | 0.97 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL24206459 | 0.97 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL20815730 | 0.97 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22348910 | 0.97 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21481061 | 0.97 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL13170049 | 0.97 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340629-A1 | BIOMARKERS FOR CANCER THERAPY | THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH (AU) | 2021-11-04 | — | — | US | disclosed |
| EP-3847282-A1 | BIOMARKERS FOR CANCER THERAPY | The Council of the Queensland Institute of Medical Research (AU) | 2021-07-14 | — | — | EP | disclosed |
| EP-2295589-A1 | Improved expression elements | Millipore Corporation (US) | 2011-03-16 | — | — | EP | disclosed |
| EP-1891223-B1 | IMPROVED EXPRESSION ELEMENTS | MILLIPORE CORP (US) | 2011-01-05 | — | — | EP | disclosed |
| US-20100015107-A1 | Expression elements | MILLIPORE CORPORATION (US) | 2010-01-21 | — | — | US | disclosed |
| US-7632661-B2 | Expression elements | MILLIPORE CORPORATION (US) | 2009-12-15 | — | — | US | disclosed |
| US-20080097088-A1 | Expression elements | EMD MILLIPORE CORPORATION | 2008-04-24 | — | — | US | disclosed |
| EP-1891223-A2 | IMPROVED EXPRESSION ELEMENTS | MILLIPORE CORPORATION (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006123097-A2 | IMPROVED EXPRESSION ELEMENTS | MILLIPORE CORPORATION (US) | 2006-11-23 | — | — | WO | disclosed |